Molbio Diagnostics Ltd.
•₹ 1,098.455.96%
2026-08-21
PROS
- Operating margins have improved to 18.8% from 12.3%
- Company comfortably covers its interest (9.5x coverage)
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- Operating cash flow has been negative in recent years
- Receivables are growing faster than sales - a possible quality concern
- Total debt has risen sharply - up 1821.9% year on year
- Equity base is being diluted - shares outstanding up 400.3%
- Recurring exceptional / one-off items are inflating headline profit
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | LENSKART | 639.30 | 169.67 | 111193.84 | 0.00 | 2284.30 | 3634.35 | 27141.80 | 1332.69 | 12.55 | 21.70 |
| 2. | POLYMED | 1771.60 | 56.99 | 17957.20 | 0.20 | 85.27 | -8.39 | 525.38 | 30.30 | 14.05 | 24.11 |
| 3. | MOLBIO | 1040.35 | 71.97 | 11988.99 | 0.00 | — | — | — | — | 19.79 | — |
| 4. | LAXMIDENTL | 195.65 | 34.85 | 1076.50 | 0.00 | 10.32 | 23.83 | 74.70 | 16.13 | 24.96 | 20.26 |
| 5. | 3BBLACKBIO | 1145.55 | 17.71 | 983.19 | 0.44 | 8.98 | -28.99 | 33.49 | 50.59 | 26.03 | 25.45 |
| 6. | GKB | 63.95 | 9.94 | 32.23 | 0.00 | 1.85 | 387.99 | 33.04 | 2.26 | 8.82 | 7.97 |
Detailed Comparison with:
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
No standalone quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 327 | 756 | 971 | 1,313 | |
| 286 | 553 | 746 | 1,062 | |
| Operating Profit | 48 | 210 | 232 | 260 |
| OPM % | 15 | 28 | 24 | 20 |
| Other Income | 8 | 7 | 6 | 8 |
| Interest | 6 | 8 | 9 | 23 |
| Depreciation | 19 | 24 | 26 | 36 |
| 23 | 152 | 188 | 198 | |
| Tax % | 32 | 27 | 26 | 27 |
| Net Profit | 16 | 111 | 140 | 145 |
| EPS | 69 | 493 | 62 | 13 |
| Dividend Payout % | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 |
| Adjusted EPS | 1 | 10 | 12 | 13 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 |
| Adjusted EPS | 1 | 10 | 12 | 13 |
Mar 2023
- 327
- 286
- Operating Profit
- 48
- OPM %
- 15
- Other Income
- 8
- Interest
- 6
- Depreciation
- 19
- 23
- Tax %
- 32
- Net Profit
- 16
- EPS
- 69
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 1
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 1
Mar 2024
- 756
- 553
- Operating Profit
- 210
- OPM %
- 28
- Other Income
- 7
- Interest
- 8
- Depreciation
- 24
- 152
- Tax %
- 27
- Net Profit
- 111
- EPS
- 493
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 10
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 10
Mar 2025
- 971
- 746
- Operating Profit
- 232
- OPM %
- 24
- Other Income
- 6
- Interest
- 9
- Depreciation
- 26
- 188
- Tax %
- 26
- Net Profit
- 140
- EPS
- 62
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 12
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 12
Mar 2026
- 1,313
- 1,062
- Operating Profit
- 260
- OPM %
- 20
- Other Income
- 8
- Interest
- 23
- Depreciation
- 36
- 198
- Tax %
- 27
- Net Profit
- 145
- EPS
- 13
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 13
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 13
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 59%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 110%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 14%
- Last Year:
- 14%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| LIABILITIES | - | - | - | - |
| Equity Capital | 2 | 2 | 2 | 11 |
| 736 | 847 | 988 | 1,123 | |
| 52 | 41 | 0 | 103 | |
| Trade Payables | 75 | 96 | 235 | 180 |
| 49 | 68 | 41 | 275 | |
| Total Liabilities | 913 | 1,054 | 1,266 | 1,692 |
| ASSETS | - | - | - | - |
| 189 | 176 | 215 | 257 | |
| Capital Work in Progress | 0 | 2 | 18 | 6 |
| 54 | 54 | 95 | 317 | |
| 328 | 293 | 410 | 397 | |
| 173 | 360 | 228 | 359 | |
| Cash & Bank | 5 | 18 | 111 | 109 |
| 165 | 152 | 190 | 248 | |
| Total Assets | 913 | 1,054 | 1,266 | 1,692 |
| Total Debt | 54 | 66 | 17 | 335 |
| Net Working Capital | 433 | 514 | 523 | 622 |
| Contingent Liabilities | 32 | 109 | 173 | 236 |
| Book Value per Share | 3276.95 | 3769.45 | 438.86 | 100.63 |
| Face Value | 10.00 | 10.00 | 1.00 | 1.00 |
| Total Debt | 54 | 66 | 17 | 335 |
| Net Working Capital | 433 | 514 | 523 | 622 |
| Contingent Liabilities | 32 | 109 | 173 | 236 |
| Book Value per Share | 3276.95 | 3769.45 | 438.86 | 100.63 |
| Face Value | 10.00 | 10.00 | 1.00 | 1.00 |
Mar 2023
- Equity Capital
- 2
- 736
- 52
- Trade Payables
- 75
- 49
- Total Liabilities
- 913
- 189
- Capital Work in Progress
- 0
- 54
- 328
- 173
- Cash & Bank
- 5
- 165
- Total Assets
- 913
- Total Debt
- 54
- Net Working Capital
- 433
- Contingent Liabilities
- 32
- Book Value per Share
- 3276.95
- Face Value
- 10.00
- Total Debt
- 54
- Net Working Capital
- 433
- Contingent Liabilities
- 32
- Book Value per Share
- 3276.95
- Face Value
- 10.00
Mar 2024
- Equity Capital
- 2
- 847
- 41
- Trade Payables
- 96
- 68
- Total Liabilities
- 1,054
- 176
- Capital Work in Progress
- 2
- 54
- 293
- 360
- Cash & Bank
- 18
- 152
- Total Assets
- 1,054
- Total Debt
- 66
- Net Working Capital
- 514
- Contingent Liabilities
- 109
- Book Value per Share
- 3769.45
- Face Value
- 10.00
- Total Debt
- 66
- Net Working Capital
- 514
- Contingent Liabilities
- 109
- Book Value per Share
- 3769.45
- Face Value
- 10.00
Mar 2025
- Equity Capital
- 2
- 988
- 0
- Trade Payables
- 235
- 41
- Total Liabilities
- 1,266
- 215
- Capital Work in Progress
- 18
- 95
- 410
- 228
- Cash & Bank
- 111
- 190
- Total Assets
- 1,266
- Total Debt
- 17
- Net Working Capital
- 523
- Contingent Liabilities
- 173
- Book Value per Share
- 438.86
- Face Value
- 1.00
- Total Debt
- 17
- Net Working Capital
- 523
- Contingent Liabilities
- 173
- Book Value per Share
- 438.86
- Face Value
- 1.00
Mar 2026
- Equity Capital
- 11
- 1,123
- 103
- Trade Payables
- 180
- 275
- Total Liabilities
- 1,692
- 257
- Capital Work in Progress
- 6
- 317
- 397
- 359
- Cash & Bank
- 109
- 248
- Total Assets
- 1,692
- Total Debt
- 335
- Net Working Capital
- 622
- Contingent Liabilities
- 236
- Book Value per Share
- 100.63
- Face Value
- 1.00
- Total Debt
- 335
- Net Working Capital
- 622
- Contingent Liabilities
- 236
- Book Value per Share
- 100.63
- Face Value
- 1.00
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 68 | 38 | 249 | -38 | |
| Cash from Investing | -51 | -31 | -98 | -256 |
| Cash from Financing | 31 | -24 | -17 | 292 |
| 48 | -18 | 133 | -2 | |
| Free Cash Flow | 68 | 26 | 170 | -101 |
| OCF / Net Profit | 4.37 | 0.34 | 1.78 | -0.26 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 |
| OCF / Net Profit | 4.37 | 0.34 | 1.78 | -0.26 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 |
Mar 2023
- 68
- Cash from Investing
- -51
- Cash from Financing
- 31
- 48
- Free Cash Flow
- 68
- OCF / Net Profit
- 4.37
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 4.37
- Cumulative 5-Year FCF
- 0
Mar 2024
- 38
- Cash from Investing
- -31
- Cash from Financing
- -24
- -18
- Free Cash Flow
- 26
- OCF / Net Profit
- 0.34
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.34
- Cumulative 5-Year FCF
- 0
Mar 2025
- 249
- Cash from Investing
- -98
- Cash from Financing
- -17
- 133
- Free Cash Flow
- 170
- OCF / Net Profit
- 1.78
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.78
- Cumulative 5-Year FCF
- 0
Mar 2026
- -38
- Cash from Investing
- -256
- Cash from Financing
- 292
- -2
- Free Cash Flow
- -101
- OCF / Net Profit
- -0.26
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- -0.26
- Cumulative 5-Year FCF
- 0
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| PER SHARE | - | - | - | - |
| EPS (₹) | 68.97 | 492.93 | 61.98 | 12.83 |
| Book Value (₹) | 3276.95 | 3769.45 | 438.86 | 100.63 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 3.10 | 11.95 | 14.73 | 16.00 |
| PROFITABILITY | - | - | - | - |
| Operating Margin % | 12.27% | 26.93% | 22.53% | 18.84% |
| Net Margin % | 4.76% | 14.69% | 13.96% | 10.82% |
| ROE % | 2.10% | 13.99% | 15.20% | 13.61% |
| ROCE % | 3.63% | 18.66% | 20.47% | 17.82% |
| 1.70% | 11.30% | 12.05% | 9.78% | |
| EFFICIENCY | - | - | - | - |
| Debtor Days | 194 | 129 | 107 | 80 |
| Inventory Days | 366 | 150 | 128 | 110 |
| Payable Days | 201 | 115 | 159 | 150 |
| 359 | 164 | 76 | 40 | |
| FINANCIAL HEALTH | - | - | - | - |
| Debt to Equity (x) | 0.07x | 0.08x | 0.02x | 0.29x |
| Interest Coverage (x) | 4.85x | 20.96x | 22.22x | 9.53x |
| 3.44x | 3.45x | 2.72x | 2.63x | |
| GROWTH | - | - | - | - |
| Revenue Growth % | 0.00% | 131.59% | 28.42% | 35.23% |
| Operating Profit Growth % | 0.00% | 336.25% | 10.37% | 11.88% |
| Net Profit Growth % | 0.00% | 614.69% | 25.84% | 3.44% |
| 0.00% | 614.69% | -87.43% | -79.30% | |
| VALUATION | - | - | - | - |
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% |
| 1.08x | 0.24x | -0.39x | 0.91x |
Mar 2023
- EPS (₹)
- 68.97
- Book Value (₹)
- 3276.95
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 3.10
- Operating Margin %
- 12.27%
- Net Margin %
- 4.76%
- ROE %
- 2.10%
- ROCE %
- 3.63%
- 1.70%
- Debtor Days
- 194
- Inventory Days
- 366
- Payable Days
- 201
- 359
- Debt to Equity (x)
- 0.07x
- Interest Coverage (x)
- 4.85x
- 3.44x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 1.08x
Mar 2024
- EPS (₹)
- 492.93
- Book Value (₹)
- 3769.45
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 11.95
- Operating Margin %
- 26.93%
- Net Margin %
- 14.69%
- ROE %
- 13.99%
- ROCE %
- 18.66%
- 11.30%
- Debtor Days
- 129
- Inventory Days
- 150
- Payable Days
- 115
- 164
- Debt to Equity (x)
- 0.08x
- Interest Coverage (x)
- 20.96x
- 3.45x
- Revenue Growth %
- 131.59%
- Operating Profit Growth %
- 336.25%
- Net Profit Growth %
- 614.69%
- 614.69%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.24x
Mar 2025
- EPS (₹)
- 61.98
- Book Value (₹)
- 438.86
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 14.73
- Operating Margin %
- 22.53%
- Net Margin %
- 13.96%
- ROE %
- 15.20%
- ROCE %
- 20.47%
- 12.05%
- Debtor Days
- 107
- Inventory Days
- 128
- Payable Days
- 159
- 76
- Debt to Equity (x)
- 0.02x
- Interest Coverage (x)
- 22.22x
- 2.72x
- Revenue Growth %
- 28.42%
- Operating Profit Growth %
- 10.37%
- Net Profit Growth %
- 25.84%
- -87.43%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- -0.39x
Mar 2026
- EPS (₹)
- 12.83
- Book Value (₹)
- 100.63
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 16.00
- Operating Margin %
- 18.84%
- Net Margin %
- 10.82%
- ROE %
- 13.61%
- ROCE %
- 17.82%
- 9.78%
- Debtor Days
- 80
- Inventory Days
- 110
- Payable Days
- 150
- 40
- Debt to Equity (x)
- 0.29x
- Interest Coverage (x)
- 9.53x
- 2.63x
- Revenue Growth %
- 35.23%
- Operating Profit Growth %
- 11.88%
- Net Profit Growth %
- 3.44%
- -79.30%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.91x
Documents
Announcements
- Trading Window
2026-08-20 - Molbio Diagnostics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Annual Reports
Nothing filed yet.
Credit Ratings
Nothing filed yet.
Concalls
Nothing filed yet.